Atezolizumab
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
| ID | DRUG-ATEZOLIZUMAB |
|---|---|
| Type | Médicament |
| Alias | TécentriqTecentriq Hybreza (SC)Атезолізумаб |
| État | reviewed 2026-04-26 | pending_clinical_signoff |
| Maladies | DIS-HCC DIS-NSCLC |
| Sources | SRC-AASLD-HCC-2023 SRC-NCCN-HCC-2025 |
Faits sur les drogues
| Catégorie | Anticorps monoclonal anti-PD-L1 humanisé IgG1-kappa (inhibiteur du point de contrôle immunitaire) |
|---|---|
| Mécanisme | Humanized IgG1 monoclonal antibody (with engineered Fc that abrogates ADCC) binding programmed death-ligand 1 (PD-L1) on tumor cells and tumor-infiltrating immune cells. Blocks both PD-L1/PD-1 and PD-L1/B7-1 (CD80) interactions, restoring T-cell antitumor immunity. Anti-PD-L1 mechanism (vs anti-PD-1 of pembro/nivo) preserves PD-1/PD-L2 signaling — a theoretical lower autoimmune-toxicity profile, though clinical irAE spectrum is similar. Pivotal HCC role: atezolizumab + bevacizumab (IMbrave150) — first ICI combination to surpass sorafenib in 1L unresectable HCC. |
| Dose typique | Standard: 1200 mg IV q3w OR 840 mg IV q2w OR 1680 mg IV q4w. HCC IMbrave150: atezolizumab 1200 mg + bevacizumab 15 mg/kg q3w until progression / unacceptable toxicity. NSCLC adjuvant (IMpower010, PD-L1 ≥1%): 1200 mg q3w × 16 cycles. SCLC IMpower133: 1200 mg q3w with carboplatin AUC 5 + etoposide 100 mg/m² × 4 cycles, then atezo q3w maintenance. Subcutaneous Tecentriq Hybreza (FDA 2024): 1875 mg SC q3w (with hyaluronidase co-formulation), ~7 min injection. |
| Ukraine enregistrée | Vrai |
| NSZU remboursé | Vrai |
| Ukraine vérifiée pour la dernière fois | 2026-04-27 |
Notes
IMbrave150 prerequisites for HCC combo: Child-Pugh A, ECOG ≤1, EGD within 6 mo with treated high-risk varices (banding/ligation), no recent variceal bleed, no active GI bleeding, controlled BP, no significant proteinuria (UPCR <1 or 24-h urine <1 g). mOS 19.2 mo (vs 13.4 mo sorafenib). Major caveat: bevacizumab risks (perforation, hemorrhage, HTN, proteinuria) compound — strict patient selection. Standard ICI irAE management protocols apply (baseline TFTs / cortisol / LFTs / renal panel, serial labs, prompt steroids for Grade ≥2 irAE). IMpassion131 (TNBC paclitaxel combo) failed primary endpoint — TNBC indication withdrawn in US 2021; nab-paclitaxel combo (IMpassion130) still approved in some EU markets.
Utilisé par
Contraindications
CI-PEMBROLIZUMAB-AUTOIMMUNE- CI-PEMBROLIZUMAB-AUTOIMMUNE
Protocole thérapeutique
REG-ATEZO-ADJUVANT-NSCLC- Atezolizumab adjuvant (resected NSCLC, 1 year)REG-ATEZO-BEV- Atezolizumab + BevacizumabREG-EP-ATEZO-SCLC- Etoposide-platine + atezolizumab (largeur SCLC, 1L)